Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Chizuru Iwasawa"'
Autor:
Ryota Tamura, Hiroyuki Miyoshi, Oltea Sampetrean, Munehisa Shinozaki, Yukina Morimoto, Chizuru Iwasawa, Raita Fukaya, Yutaka Mine, Hirotaka Masuda, Tetsuo Maruyama, Minoru Narita, Hideyuki Saya, Kazunari Yoshida, Hideyuki Okano, Masahiro Toda
Publikováno v:
Molecular Brain, Vol 12, Iss 1, Pp 1-10 (2019)
Abstract Glioblastoma exhibits phenotypic and genetic heterogeneity, aggressive invasiveness, therapeutic resistance, and tumor recurrence, which can be explained by the existence of glioma stem cells (GSCs). In this study, we visualized the spatiote
Externí odkaz:
https://doaj.org/article/b28eb4eb9715437ea41904cdee4f5d83
Autor:
Chizuru Iwasawa, Naoko Kuzumaki, Yukari Suda, Reiko Kagawa, Yuko Oka, Nobutaka Hattori, Hideyuki Okano, Minoru Narita
Publikováno v:
Molecular Brain, Vol 12, Iss 1, Pp 1-8 (2019)
Abstract Parkinson’s disease (PD) is associated with both motor and non-motor symptoms, including constipation, sensory neuropathy, depression, dementia and sleep disorder. Somatostatin (SST) is considered to be a modulator of GABAergic inhibitory
Externí odkaz:
https://doaj.org/article/e1613ec921ab428494bbcb51a59fadeb
Autor:
Yukari Suda, Naoko Kuzumaki, Takefumi Sone, Michiko Narita, Kenichi Tanaka, Yusuke Hamada, Chizuru Iwasawa, Masahiro Shibasaki, Aya Maekawa, Miri Matsuo, Wado Akamatsu, Nobutaka Hattori, Hideyuki Okano, Minoru Narita
Publikováno v:
Molecular Brain, Vol 11, Iss 1, Pp 1-9 (2018)
Abstract Ghrelin exerts a wide range of physiological actions throughout the body and appears to be a promising target for disease therapy. Endogenous ghrelin receptors (GHSRs) are present in extrahypothalamic sites including the substantia nigra par
Externí odkaz:
https://doaj.org/article/0359de8efc2a4330aaff8581b05f2de0
Autor:
Michiko Narita, Eri Shimura, Atsumi Nagasawa, Toshiki Aiuchi, Yukari Suda, Yusuke Hamada, Daigo Ikegami, Chizuru Iwasawa, Kazuhiko Arakawa, Katsuhide Igarashi, Naoko Kuzumaki, Yusuke Yoshioka, Takahiro Ochiya, Hideyuki Takeshima, Toshikazu Ushijima, Minoru Narita
Publikováno v:
PLoS ONE, Vol 12, Iss 2, p e0172115 (2017)
BACKGROUND:The EGFR tyrosine kinase inhibitor gefitinib is used in therapy for non-small-cell lung cancer (NSCLC). However, its application is limited by resistance-accelerated disease progression, which is accompanied by the epithelial-to-mesenchyma
Externí odkaz:
https://doaj.org/article/92670937bf7d4b1691a399c5a2b67d9f
Autor:
Oltea Sampetrean, Chizuru Iwasawa, Ryota Tamura, Kazunari Yoshida, Masahiro Toda, Yutaka Mine, Hiroyuki Miyoshi, Yukina Morimoto, Hideyuki Okano, Hideyuki Saya, Yumiko Oishi
Publikováno v:
Human Gene Therapy. 31:352-366
Glioblastoma is the most aggressive brain tumor characterized by diffuse infiltration into the normal brain parenchyma. Neural stem cells are known to possess the tumor-tropic migratory capacity and thus can be used as cellular vehicles for targeted
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e45d0e8fae4d15a5982ccfdac9b770b1
https://doi.org/10.1089/hum.2019.326
https://doi.org/10.1089/hum.2019.326
Autor:
Vivianne L. Tawfik, Wado Akamatsu, Toshikazu Ushijima, Takefumi Sone, Chizuru Iwasawa, Naoko Kuzumaki, Hideyuki Okano, Aya Maekawa, Hideyuki Takeshima, Katsuhide Igarashi, Hideki Tamura, Moe Watanabe, Michiko Narita, Minoru Narita, Takuya Matsumoto, Nobutaka Hattori, Yukari Suda
Publikováno v:
Brain. 142:1675-1689
The mechanism by which dopaminergic neurons are selectively affected in Parkinson's disease is not fully understood. In this study, we found a dramatic increase in the expression of catechol-O-methyltransferase (COMT), along with a lower level of DNA
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8808f6491db994e7454a0054e5f87d83
https://doi.org/10.1093/brain/awz084
https://doi.org/10.1093/brain/awz084
Autor:
Masahiro Toda, Hiroyuki Miyoshi, Chizuru Iwasawa, Ryota Tamura, Naoko Kuzumaki, Makoto Suematsu, Masaya Nakamura, Hideyuki Okano, Sadafumi Suzuki, Yuki Sugiura, Kazunari Yoshida, Minoru Narita
Publikováno v:
International Journal of Molecular Sciences
International Journal of Molecular Sciences, Vol 20, Iss 4, p 810 (2019)
Volume 20
Issue 4
International Journal of Molecular Sciences, Vol 20, Iss 4, p 810 (2019)
Volume 20
Issue 4
Human induced pluripotent stem cells (iPSCs) hold enormous promise for regenerative medicine. The major safety concern is the tumorigenicity of transplanted cells derived from iPSCs. A potential solution would be to introduce a suicide gene into iPSC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c2f9f8191c4b9d22c2adb674148b9f32
http://europepmc.org/articles/PMC6413063
http://europepmc.org/articles/PMC6413063
Autor:
Yuko Oka, Reiko Kagawa, Hideyuki Okano, Chizuru Iwasawa, Yukari Suda, Minoru Narita, Naoko Kuzumaki, Nobutaka Hattori
Publikováno v:
Molecular Brain, Vol 12, Iss 1, Pp 1-8 (2019)
Molecular Brain
Molecular Brain
Parkinson’s disease (PD) is associated with both motor and non-motor symptoms, including constipation, sensory neuropathy, depression, dementia and sleep disorder. Somatostatin (SST) is considered to be a modulator of GABAergic inhibitory transmiss
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4627009945280329721d78e2bae906ae
https://doi.org/10.1186/s13041-019-0426-7
https://doi.org/10.1186/s13041-019-0426-7
Autor:
Wado Akamatsu, Takefumi Sone, Hideyuki Okano, Chizuru Iwasawa, Naoko Kuzumaki, Miri Matsuo, Masahiro Shibasaki, Michiko Narita, Minoru Narita, Nobutaka Hattori, Kenichi Tanaka, Yusuke Hamada, Aya Maekawa, Yukari Suda
Publikováno v:
Molecular Brain
Molecular Brain, Vol 11, Iss 1, Pp 1-9 (2018)
Molecular Brain, Vol 11, Iss 1, Pp 1-9 (2018)
Ghrelin exerts a wide range of physiological actions throughout the body and appears to be a promising target for disease therapy. Endogenous ghrelin receptors (GHSRs) are present in extrahypothalamic sites including the substantia nigra pars compact
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3880a130ce4f988672f67936f02e86c1
https://pubmed.ncbi.nlm.nih.gov/29458391
https://pubmed.ncbi.nlm.nih.gov/29458391
Autor:
Kazuhiko Arakawa, Yusuke Yoshioka, Chizuru Iwasawa, Toshiki Aiuchi, Daigo Ikegami, Takahiro Ochiya, Naoko Kuzumaki, Hideyuki Takeshima, Atsumi Nagasawa, Eri Shimura, Michiko Narita, Minoru Narita, Yusuke Hamada, Katsuhide Igarashi, Yukari Suda, Toshikazu Ushijima
Publikováno v:
PLoS ONE, Vol 12, Iss 2, p e0172115 (2017)
PLoS ONE
PLoS ONE
Background The EGFR tyrosine kinase inhibitor gefitinib is used in therapy for non-small-cell lung cancer (NSCLC). However, its application is limited by resistance-accelerated disease progression, which is accompanied by the epithelial-to-mesenchyma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f969fe8b3cab7c5c973267d58f1f86a5
http://europepmc.org/articles/PMC5321411?pdf=render
http://europepmc.org/articles/PMC5321411?pdf=render